Previous 10 | Next 10 |
home / stock / scyx / scyx articles
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action laws...
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds invest...
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons...
NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action laws...
LOS ANGELES, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on ...
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed aga...
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action lawsuit on behalf of persons...
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "C...
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigati...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...